Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, State University of New Jersey, 164 Frelinghuysen Road, Piscataway, New Jersey 08854- 8020, USA.
J Clin Invest. 2013 Feb;123(2):556-8. doi: 10.1172/JCI67589. Epub 2013 Jan 25.
The major constituent of green tea, (-)-epigallocatechin-3-O-gallate (EGCG), has been shown to have cancer-preventive and therapeutic activities. Numerous molecular targets for EGCG have been proposed, but the mechanisms of its anticancer activities are not clearly understood. In this issue of the JCI, Kumazoe et al. report that EGCG activates 67-kDa laminin receptor (67LR), elevates cGMP levels, and induces cancer cell apoptosis. Furthermore, a phosphodiesterase 5 inhibitor, vardenafil, synergizes with EGCG to induce cancer cell death. This is a provocative observation with important implications for cancer therapy. It also raises several issues for further investigation, such as the mechanism by which EGCG specifically activates 67LR.
绿茶的主要成分 (-)-表没食子儿茶素-3-O-没食子酸酯（EGCG）已被证明具有预防和治疗癌症的作用。已经提出了 EGCG 的许多分子靶标，但它的抗癌活性的机制尚不清楚。在本期 JCI 中，Kumazoe 等人报告 EGCG 激活 67 kDa 层粘连蛋白受体（67LR），提高 cGMP 水平，并诱导癌细胞凋亡。此外，磷酸二酯酶 5 抑制剂伐地那非与 EGCG 协同诱导癌细胞死亡。这是一个具有挑战性的观察结果，对癌症治疗具有重要意义。它还提出了一些需要进一步研究的问题，例如 EGCG 如何特异性激活 67LR 的机制。
